Non classifié(e)

ACSÉ-ESMART TRIAL

ACSÉ-ESMART TRIAL

ACSÉ-ESMART TRIAL

GIVING ACCESS TO INNOVATIVE TREATMENTS FOR CHILDREN IN RELAPSE OR WITH THERAPEUTIC FAILURE, FOR ANY TYPE OF CANCER (UNIQUE IN THE WORLD)  This trial has been co-financed with the Children without Cancer races of 2015 and 2019. ESMART – European Proof-of-concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed of Refractory Tumors in children   AcSé-ESMART (ITCC-057) is a phase I […]

Biomede trial

Biomede trial

Biomede trial

This trial was co-financed with the Children without Cancer races of 2014 and 2017. BIOMEDE – Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication   BIOMEDE therapeutic trial enables to test three target therapies: everolimus, dasatinib, erlotinib. in combination with radiotherapy, upon initial diagnosis, according to the molecular analysis of the child’s tumor upon diagnosis (one […]

Beacon trial

Beacon trial

Beacon trial

RESEARCH OF NEW TREATMENTS FOR HIGH RISK NEUROBLASTOMA IN RELAPSE  This trial was cofinanced by the 2013 and 2018 Children without Cancer races. BEACON – a randomised phase IIb trial of BEyACizumab added to temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma     BEACON (ITCC-032) is a phase-II trial on high risk neuroblastoma in relapse, second […]

SEMINAR 2017 : « Towards a targeted research on children’s cancers »

SEMINAR 2017 : « Towards a targeted research on children’s cancers »

SEMINAR 2017 : « Towards a targeted research on children’s cancers »

On 28th January, took place our 4th seminar “Towards a targeted research on children’s cancer”. All major players in the cause of childhood cancer were present, including doctors, researchers, institutions, politicians, associations and parents. We have been able to show that a strong dynamic has started with new and particularly innovative research programs of targeted […]